Cardiac Amyloidosis: When the Presentation Misleads

Case reports · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Follow physiology across organ systems, then confirm the specific disease.

A light-chain clone can injure the heart. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

A light-chain clone can injure the heart. Plasma-cell clone — Produces a monoclonal light chain; Circulating protein — Toxicity and deposition; Cardiac involvement — Restricted filling and impaired forward flow; Variable kidney involvement — Heavy proteinuria is not required. Absence of marked urine protein does not exclude cardiac AL. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

A presentation outside cardiology

Ascites, kidney dysfunction, or apparent liver disease may be driven partly by cardiac congestion. Revisit the working diagnosis when the history and physiology do not fit the initial label.

Ejection fraction has limits

Preserved ejection fraction does not guarantee adequate forward flow or normal filling pressures. Chamber size, stroke volume, diastolic function, and right-sided findings add essential information.

Work through the ascites clue

In the source case, serum albumin 4.0 minus ascitic albumin 2.3 gives a SAAG of 1.7 g/dL. Coupled with protein-rich ascites, this supports portal-hypertensive physiology with a possible cardiac contribution. It redirects the workup but does not independently establish amyloidosis.

Screen for a monoclonal protein

A proper AL screen includes serum and urine immunofixation and serum free light chains. Renal impairment affects interpretation; a negative single test is not the entire screen.

Use amyloid testing correctly

Bone-tracer scintigraphy can support an ATTR pathway only under the appropriate diagnostic conditions. A monoclonal protein changes the interpretation and may require tissue typing.

Resolve type before choosing therapy

Use the full monoclonal screen, cardiac imaging, and tissue typing when indicated to separate AL from ATTR and mimics. Congestion management may need cautious adjustment when stroke volume is fixed and BP is low. Improvement after fluid removal does not prove the underlying amyloid type.

Supporting evidence

Continue learning